• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

优化所有 COVID-19 患者用药剂量的真实世界证据框架。

A Real-World Evidence Framework for Optimizing Dosing in All Patients With COVID-19.

机构信息

Clinical Pharmacology, Pharma Research & Early Development, Roche Innovation Center, Basel, Switzerland.

Pharmacometrics Consultant, Chapel Hill, North Carolina, USA.

出版信息

Clin Pharmacol Ther. 2020 Nov;108(5):921-923. doi: 10.1002/cpt.1922. Epub 2020 Jun 29.

DOI:10.1002/cpt.1922
PMID:32445484
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7283813/
Abstract

Potential treatments for coronavirus disease 2019 (COVID-19) are being investigated at unprecedented speed, and successful treatments will rapidly be used in tens or hundreds of thousands of patients. To ensure safe and effective use in all those patents it is essential also to develop, at unprecedented speed, a means to provide frequently updated, optimal dosing information for all patient subgroups. Success will require immediate collaboration between drug developers, academics, and regulators.

摘要

正在以空前的速度研究 2019 年冠状病毒病（COVID-19）的潜在治疗方法，成功的治疗方法将迅速在数万或数十万患者中使用。为确保所有患者安全有效地使用，还必须以空前的速度开发一种方法，为所有患者亚组提供经常更新的最佳剂量信息。成功将需要药物开发商、学者和监管机构之间的立即合作。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f50/7283813/7f7ded6a0423/CPT-108-921-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f50/7283813/7f7ded6a0423/CPT-108-921-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f50/7283813/7f7ded6a0423/CPT-108-921-g001.jpg

相似文献

1
A Real-World Evidence Framework for Optimizing Dosing in All Patients With COVID-19.优化所有 COVID-19 患者用药剂量的真实世界证据框架。
Clin Pharmacol Ther. 2020 Nov;108(5):921-923. doi: 10.1002/cpt.1922. Epub 2020 Jun 29.
2
COVID-19: A Defining Moment for Clinical Pharmacology?新型冠状病毒肺炎：临床药理学的决定性时刻？
Clin Pharmacol Ther. 2020 Jul;108(1):11-15. doi: 10.1002/cpt.1876.
3
COVID-19: Stay Cool toward Corticosteroids.新冠疫情：对皮质类固醇保持冷静态度。
Keio J Med. 2020 Jun 25;69(2):27-29. doi: 10.2302/kjm.2020-0007-LE. Epub 2020 May 30.
4
Time to Step Up: A Call to Action For the Clinical and Quantitative Pharmacology Community to Accelerate Therapeutics for COVID-19.加快步伐：呼吁临床和定量药理学界为 COVID-19 加速治疗药物研发。
Clin Transl Sci. 2020 Jul;13(4):646-648. doi: 10.1111/cts.12824. Epub 2020 Jun 11.
5
COVID-19 therapeutic options for patients with kidney disease.针对肾病患者的COVID-19治疗方案。
Kidney Int. 2020 Jun;97(6):1297-1298. doi: 10.1016/j.kint.2020.03.015. Epub 2020 Mar 30.
6
Science in the Wake of the Pandemic: How Will COVID-19 Change the Way We Do Research?疫情后的科学：新冠疫情将如何改变我们的研究方式？
Mol Cell. 2020 Jul 2;79(1):9-10. doi: 10.1016/j.molcel.2020.06.024.
7
Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19.关于新型冠状病毒肺炎患者使用羟氯喹负荷剂量的建议。
Int J Antimicrob Agents. 2020 Sep;56(3):106123. doi: 10.1016/j.ijantimicag.2020.106123. Epub 2020 Jul 30.
8
COVID-19: Small-Molecule Clinical Trials Landscape.新冠病毒病（COVID-19）：小分子药物临床试验全景
Curr Top Med Chem. 2020;20(18):1577-1580. doi: 10.2174/156802662018200703154334.
9
Cationic drugs and COVID-19.阳离子药物与 COVID-19。
Int J Immunopathol Pharmacol. 2020 Jan-Dec;34:2058738420966078. doi: 10.1177/2058738420966078.
10
Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19.COVID-19时代严格的随机对照试验实施
Am J Trop Med Hyg. 2020 Jun;102(6):1154-1155. doi: 10.4269/ajtmh.20-0262.

引用本文的文献

1
Personalized health and the coronavirus vaccines-Do individual genetics matter?个性化健康与冠状病毒疫苗——个体遗传学是否重要？
Bioessays. 2021 Sep;43(9):e2100087. doi: 10.1002/bies.202100087. Epub 2021 Jul 26.
2
Real-world evidence and product development: Opportunities, challenges and risk mitigation.真实世界证据与产品开发：机遇、挑战与风险缓解。
Wien Klin Wochenschr. 2021 Aug;133(15-16):840-846. doi: 10.1007/s00508-021-01851-w. Epub 2021 Apr 9.

本文引用的文献

1
Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load.抗病毒治疗的时机对于降低 SARS-CoV-2 病毒载量至关重要。
CPT Pharmacometrics Syst Pharmacol. 2020 Sep;9(9):509-514. doi: 10.1002/psp4.12543. Epub 2020 Aug 7.
2
Drug Dosing Recommendations for All Patients: A Roadmap for Change.所有患者的药物剂量推荐：变革路线图。
Clin Pharmacol Ther. 2021 Jan;109(1):65-72. doi: 10.1002/cpt.1923. Epub 2020 Jul 12.
3
Challenges in Drug Development Posed by the COVID-19 Pandemic: An Opportunity for Clinical Pharmacology.
新冠疫情给药物研发带来的挑战：临床药理学的机遇。
Clin Pharmacol Ther. 2020 Oct;108(4):699-702. doi: 10.1002/cpt.1879. Epub 2020 May 28.
4
Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.优化 COVID-19 患者的羟氯喹剂量：一种有效的药物再利用的综合建模方法。
Clin Pharmacol Ther. 2020 Aug;108(2):253-263. doi: 10.1002/cpt.1856. Epub 2020 May 12.
5
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.药物治疗 2019 冠状病毒病（COVID-19）：综述。
JAMA. 2020 May 12;323(18):1824-1836. doi: 10.1001/jama.2020.6019.
6
The gendered dimensions of COVID-19.新冠疫情的性别层面
Lancet. 2020 Apr 11;395(10231):1168. doi: 10.1016/S0140-6736(20)30823-0.
7
CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications.CYP 介导的治疗性蛋白-药物相互作用：临床发现、提出的机制和监管影响。
Clin Pharmacokinet. 2010 May;49(5):295-310. doi: 10.2165/11319980-000000000-00000.